65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. Issue 8 (August 2018)

• Record Type: Journal Article
• Authors: Syro, Luis V; Rotondo, Fabio; Ortiz, Leon D; Kovacs, Kalman
• Is Part Of: Endocrine-related cancer. Volume 25:Issue 8(2018)
• Page Start: T159
• Page End: T169
• Publication Date: 2018-08
• Subjects: chemotherapy -- neoplasms -- neuroendocrine tumors -- pituitary -- temozolomide; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-18-0015
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance.